Announcements Trials

Browse Landscape

Phase

Phase 2 2 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Ovarian Neoplasms 4 Carcinoma, Transitional Cell 3 Carcinoma, Non-Small-Cell Lung 3 Urinary Bladder Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Neoplasms 2 Carcinoma, Renal Cell 2 Urologic Neoplasms 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Recurrence 1 Neoplasm Metastasis 1 Microsatellite Instability 1 Lymphoma, Large B-Cell, Diffuse 1 Kidney Neoplasms 1 Kidney Diseases 1 Head and Neck Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Merkel Cell 1

Interventions

Fluorouracil 72 Leucovorin 71 Oxaliplatin 47 Irinotecan 31 Capecitabine 24 Bevacizumab 23 Folfox protocol 20 Cetuximab 15 Chemotherapy, Adjuvant 13 Celecoxib 7 Aspirin 6 Laparoscopy 5 XELOX 4 Panitumumab 4 Neoadjuvant Therapy 4 Levamisole 4 dehydroftorafur 3 Tegafur 3 Surgical Procedures, Operative 3 Observation 3 Floxuridine 3 vatalanib 2 tislelizumab 2 pertuzumab 2 encorafenib 2 atezolizumab 2 Trastuzumab 2 Standard of Care 2 Semaxinib 2 Selenium 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Colonic Neoplasms × avelumab × Clear all

NCT03827044 2022-10-07

POLEM

Royal Marsden NHS Foundation Trust

Phase 3 Terminated

Gastrointestinal

Colonic Neoplasms, Microsatellite Instability

Data powered by HemOnc (CC BY 4.0) Colophon ⚡